IDEXX Reports Strong 2025 Financials with Double-Digit Revenue Growth and Increased Share Repurchases
IDXX sits 78% above its 52-week low of $356.14.
Summary
IDEXX Laboratories Inc. delivered robust financial results for fiscal year 2025, reporting significant increases in revenue, net income, and EPS, alongside substantial share repurchases.
Key Events · Earnings and Guidance · IDXX
-
Strong Financial Performance
Total revenue grew 10.4% to $4.3 billion, net income rose to $1.06 billion, and diluted EPS reached $13.08 for fiscal year 2025, demonstrating robust operational execution.
-
Significant Share Repurchases
The company repurchased $1.23 billion of common stock in 2025, a substantial increase from the prior year, reflecting a strong commitment to returning value to shareholders.
-
Healthy Financial Position
IDEXX maintains a strong balance sheet with a consolidated leverage ratio of 0.54, well below the 3.5-to-1 covenant, and $850.2 million in remaining borrowing availability under its credit facility.
-
Positive 2026 Outlook
Management anticipates favorable foreign currency impacts to increase 2026 revenues by approximately $28 million, operating profit by $22 million, and diluted EPS by $0.22 per share.
Analysis · IDXX · Life Sciences
IDEXX Laboratories Inc. has reported robust financial performance for fiscal year 2025, marked by significant growth across key metrics and a substantial return of capital to shareholders. The Companion Animal Group (CAG) segment, the company's primary business, was a major driver of this growth. The company's strong liquidity and low leverage ratio indicate a healthy financial position, providing flexibility for future strategic initiatives. The outlook for 2026, including anticipated positive foreign currency impacts, suggests continued growth. The resolution of a prior litigation matter, with the $80 million payment having been accrued in previous years, removes a potential overhang.
At the time of this filing, IDXX was trading at $635.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $50.8B. The 52-week trading range was $356.14 to $769.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.